The Safety and Efficacy of the Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Back Pain.
Status:
Completed
Trial end date:
1998-05-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess the safety of the buprenorphine transdermal system
(5, 10, and 20) in comparison to placebo transdermal system and immediate release oxycodone/
acetaminophen in subjects with chronic back pain. The double-blind treatment intervention
duration is 84 days during which time supplemental analgesic medication (non-steroidal
anti-inflammatory drugs) will be allowed for all subjects in addition to study drug.
Phase:
Phase 3
Details
Lead Sponsor:
Purdue Pharma LP
Treatments:
Acetaminophen Acetaminophen, hydrocodone drug combination Buprenorphine Oxycodone